Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Malignant Mesothelioma: Time to Translate?

Napolitano A, Carbone M.

Trends Cancer. 2016 Sep;2(9):467-474. doi: 10.1016/j.trecan.2016.07.004.

PMID:
28603777
3.

Management of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging : Consensus of the Austrian Mesothelioma Interest Group (AMIG).

Geltner C, Errhalt P, Baumgartner B, Ambrosch G, Machan B, Eckmayr J, Klikovits T, Hoda MA, Popper H, Klepetko W; Austrian Mesothelioma Interest Group (AMIG).

Wien Klin Wochenschr. 2016 Sep;128(17-18):611-7. doi: 10.1007/s00508-016-1080-z. Epub 2016 Sep 12.

4.

Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.

Carbone M, Shimizu D, Napolitano A, Tanji M, Pass HI, Yang H, Pastorino S.

Oncotarget. 2016 Sep 13;7(37):59314-59321. doi: 10.18632/oncotarget.10653.

5.

Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s.

Carbone M, Flores EG, Emi M, Johnson TA, Tsunoda T, Behner D, Hoffman H, Hesdorffer M, Nasu M, Napolitano A, Powers A, Minaai M, Baumann F, Bryant-Greenwood P, Lauk O, Kirschner MB, Weder W, Opitz I, Pass HI, Gaudino G, Pastorino S, Yang H.

PLoS Genet. 2015 Dec 18;11(12):e1005633. doi: 10.1371/journal.pgen.1005633. eCollection 2015 Dec.

6.

Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Bononi A, Napolitano A, Pass HI, Yang H, Carbone M.

Expert Rev Respir Med. 2015 Oct;9(5):633-54. doi: 10.1586/17476348.2015.1081066. Epub 2015 Aug 26. Review.

7.

Distinctive clinical characteristics of malignant mesothelioma in young patients.

Thomas A, Chen Y, Yu T, Gill A, Prasad V.

Oncotarget. 2015 Jun 30;6(18):16766-73.

8.

Detection of pleural plaques in workers exposed to inhalation of natural fluoro-edenite fibres.

Rapisarda V, Ledda C, Ricceri V, Arena F, Musumeci A, Marconi A, Fago L, Bracci M, Santarelli L, Ferrante M.

Oncol Lett. 2015 May;9(5):2046-2052. Epub 2015 Feb 19.

9.

Reactive oxygen species a double-edged sword for mesothelioma.

Benedetti S, Nuvoli B, Catalani S, Galati R.

Oncotarget. 2015 Jul 10;6(19):16848-65. Review.

10.

Clinical and prognostic features of erionite-induced malignant mesothelioma.

Demirer E, Ghattas CF, Radwan MO, Elamin EM.

Yonsei Med J. 2015 Mar;56(2):311-23. doi: 10.3349/ymj.2015.56.2.311. Review.

11.

High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.

Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, Baumann F, Zhang YA, Gazdar A, Kanodia S, Tiirikainen M, Flores E, Gaudino G, Becich MJ, Pass HI, Yang H, Carbone M.

J Thorac Oncol. 2015 Apr;10(4):565-76. doi: 10.1097/JTO.0000000000000471.

12.

Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.

Tomasetti M, Santarelli L.

Cancers (Basel). 2010 Apr 14;2(2):523-48. doi: 10.3390/cancers2020523.

13.

Malignant pleural mesothelioma: current and future perspectives.

Porpodis K, Zarogoulidis P, Boutsikou E, Papaioannou A, Machairiotis N, Tsakiridis K, Katsikogiannis N, Zaric B, Perin B, Huang H, Kougioumtzi I, Spyratos D, Zarogoulidis K.

J Thorac Dis. 2013 Sep;5 Suppl 4:S397-406. doi: 10.3978/j.issn.2072-1439.2013.08.08. Review.

14.
15.

Malignant pleural mesothelioma: an epidemiological perspective.

Robinson BM.

Ann Cardiothorac Surg. 2012 Nov;1(4):491-6. doi: 10.3978/j.issn.2225-319X.2012.11.04.

16.

BAP1 and cancer.

Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G.

Nat Rev Cancer. 2013 Mar;13(3):153-9. doi: 10.1038/nrc3459. Review.

17.

Thoracic computed tomography findings in malignant mesothelioma.

Tamer Dogan O, Salk I, Tas F, Epozturk K, Gumus C, Akkurt I, Levent Ozsahin S.

Iran J Radiol. 2012 Nov;9(4):209-11. doi: 10.5812/iranjradiol.8764. Epub 2012 Nov 20.

18.

Malignant mesothelioma of the tunica vaginalis: presenting with intermittent scrotal pain and hydrocele.

Esen T, Acar O, Peker K, Sarman K, Musaoglu A, Tefekli A.

Case Rep Med. 2012;2012:189170. doi: 10.1155/2012/189170. Epub 2012 Jul 18.

19.

New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.

Ladanyi M, Zauderer MG, Krug LM, Ito T, McMillan R, Bott M, Giancotti F.

Clin Cancer Res. 2012 Sep 1;18(17):4485-90. doi: 10.1158/1078-0432.CCR-11-2375. Epub 2012 Jul 23.

20.

Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.

Nasreen N, Khodayari N, Mohammed KA.

Am J Cancer Res. 2012;2(2):222-34. Epub 2012 Feb 15.

Supplemental Content

Support Center